左西孟旦联合培哚普利叔丁胺治疗充血性心力衰竭的效果观察  

Effect of Levosimendan Combined with Perindopril Tert-Butylamine in the Treatment of Congestive Heart Failure

作　　者：齐素霞 王子月 袁莹 沈青青 Qi Suxia;Wang Ziyue;Yuan Ying;Shen Qingqing(Department of Cardiology,Xingtai Central Hospital,Xingtai 054000,China;Department of Neurology,Xingtai Central Hospital,Xingtai 054000,China)

机构地区：[1]邢台市中心医院心内科,邢台054000 [2]邢台市中心医院神经内科,邢台054000

出　　处：《成都医学院学报》2025年第1期66-69,共4页Journal of Chengdu Medical College

基　　金：河北省卫生健康委员会科研项目(No:20191677)。

摘　　要：目的探究左西孟旦联合培哚普利叔丁胺治疗充血性心力衰竭(CHF)的效果。方法选取邢台市中心医院收治的126例CHF患者为研究对象,使用抽签法将其随机分为对照组和联合组,每组63例。两组均给予基础治疗,对照组在基础治疗上给予培哚普利叔丁胺治疗,联合组在对照组基础上给予左西孟旦治疗。比较两组治疗前后心功能指标、血清NT-proBNP、CK-MB、Cys-C水平、炎症因子水平,不良反应及临床疗效。结果联合组临床疗效总有效率高于对照组(P<0.05);治疗后,两组左心室射血分数(LVEF)、每搏量(SV)水平、6 min步行距离(WT)均增加,且联合组LLVEF、SV水平、6 min WT均高于对照组(P<0.05);治疗后,两组NT-proBNP、CK-MB及Cys-C水平均降低,且联合组NT-proBNP、CK-MB及Cys-C水平低于对照组(P<0.05);治疗后,两组肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)和白细胞介素-6(IL-6)水平均降低,且联合组TNF-α、hs-CRP及IL-6水平低于对照组(P<0.05);两组不良反应差异无统计学意义(P>0.05)。结论与培哚普利叔丁胺治疗CHF相比,培哚普利叔丁胺联合左西孟旦在临床疗效、心功能、心肌损伤和炎症反应方面改善效果显著,且安全可靠。Objective To investigate the effect of levosimendan combined with perindopril tert-butylamine in the treatment of congestive heart failure(CHF).Methods A total of 126 patients with CHF admitted to Xingtai Central Hospital from January 2022 to December 2023 were included.They were randomly divided into the control group and the combination group by drawing lots,with 63 cases in each group.The control group was treated with perindopril tert-butylamine on the basis of basic treatment,while the combination group was additionally given levosimendan on the basis of the treatment in the control group.Cardiac function indicators,serum N-terminal pro-brain natriuretic peptide(NT-proBNP),creatine kinase myocardial band(CK-MB)and cystatin C(Cys-C)levels,and inflammatory factor levels before and after treatment,adverse reactions,and clinical efficacy were compared between the two groups.Results The total clinical effective rate in the combination group was higher than that in the control group(P<0.05).After treatment,both groups showed an increase in left ventricular ejection fraction(LVEF),stroke volume(SV)and 6-min walk test distance,and the above indicators in the combination group were higher than those in the control group(P<0.05).After treatment,the levels of NT-proBNP,CK-MB,Cys-C,tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)and interleukin-6(IL-6)decreased in both groups,and the above indicators in the combination group were lower than those in the control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion The combination of perindopril tert-butylamine and levosimendan in the treatment of CHF is more effective in improving clinical efficacy,cardiac function,myocardial injury,and inflammatory response than perindopril tert-butylamine alone,and is safe and reliable.

关 键 词：充血性心力衰竭 左西孟旦 培哚普利叔丁胺 

分 类 号：R541.6[医药卫生—心血管疾病]